Form 8-K - Current report:
SEC Accession No. 0000950142-25-001416
Filing Date
2025-05-19
Accepted
2025-05-19 07:31:48
Documents
13
Period of Report
2025-05-17
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K eh250629700_8k.htm   iXBRL 8-K 41918
2 EXHIBIT 99.1 eh250629700_ex9901.htm EX-99.1 17235
  Complete submission text file 0000950142-25-001416.txt   237204

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE me-20250517.xsd EX-101.SCH 3005
4 XBRL LABEL FILE me-20250517_lab.xml EX-101.LAB 34239
5 XBRL PRESENTATION FILE me-20250517_pre.xml EX-101.PRE 22354
15 EXTRACTED XBRL INSTANCE DOCUMENT eh250629700_8k_htm.xml XML 3687
Mailing Address 870 MARKET STREET ROOM 415 SAN FRANCISCO CA 94102
Business Address 870 MARKET STREET ROOM 415 SAN FRANCISCO CA 94102 (650) 938-6300
23andMe Holding Co. (Filer) CIK: 0001804591 (see all company filings)

EIN.: 871240344 | Fiscal Year End: 0331
Type: 8-K | Act: 34 | File No.: 001-39587 | Film No.: 25961496
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)